Implantation of a duodenal–jejunal bypass liner for managing type 2 diabetes

Recommendation ID: IPG518/1
Question: Current evidence on the safety and efficacy of implantation of a duodenal–jejunal bypass liner for managing type 2 diabetes is limited in quality and quantity. Therefore the procedure should only be used in the context of research.
Any explanatory notes (if applicable): Further research should give details of patient selection, including information about use of the procedure in patients with different levels of BMI. The research should provide information on complications; reasons for early removal of the device; medication used for treating type 2 diabetes, both when the device is in place and after its removal; and control of type 2 diabetes after device removal. NICE may update the guidance on publication of further evidence.

Source guidance details

Comes from guidance: Implantation of a duodenal–jejunal bypass liner for managing type 2 diabetes
Number: IPG518
Date issued: March 2015

Is this a recommendation for the use of a technology only in the context of research?	Yes
Is it a recommendation that suggests collection of data or the establishment of a register?	No
Last Reviewed	23/04/2015